2021
Cancer Immunology and the Evolution of Immunotherapy
Nurieva R, Divenko M, Kim S. Cancer Immunology and the Evolution of Immunotherapy. 2021, 3-29. DOI: 10.1007/978-3-030-56824-5_1.Peer-Reviewed Original ResearchDevelopment of cancer immunotherapeuticsHost anti-tumor immunityCancer immunotherapy modalitiesEvolution of immunotherapyAnti-tumor immunityHost immune cellsImmunotherapy modalitiesCancer immunotherapyCancer immunotherapeuticsCancer immunologyImmune cellsTumor cellsCellular mechanisms of interactionCancer cellsCancerCellular mechanismsImmunotherapyCellsImmunotherapeuticsTumorImmunityImmunologyFDAModalitiesTrials
2020
638 Plasma proteome analysis in patients with immune checkpoint inhibitors related arthritis and pneumonitis
Abdel-Wahab N, Diab A, Katayama H, Kim S, Hanash S, Suarez-Almazor M. 638 Plasma proteome analysis in patients with immune checkpoint inhibitors related arthritis and pneumonitis. Journal For ImmunoTherapy Of Cancer 2020, 8: a674-a674. DOI: 10.1136/jitc-2020-sitc2020.0638.Peer-Reviewed Original ResearchImmune-related adverse eventsImmune checkpoint inhibitorsRenal cell carcinomaNon-small cell lung carcinomaPlasma proteomic analysisStatistically significant differenceCheckpoint inhibitorsCell carcinomaAdverse eventsBiomarkers of immune-related adverse eventsDevelopment of immune-related adverse eventsPatients treated with immune checkpoint inhibitorsAnti-programmed cell death 1Immune checkpoint inhibitor initiationImmune checkpoint inhibitor treatmentResponse to ICI therapyNon-small cell lung cancerBlood drawThe University of Texas MD Anderson Cancer CenterUniversity of Texas MD Anderson Cancer CenterAnti-PD1 treatmentAnti-tumor immunityMD Anderson Cancer CenterCell death 1Inflammation of lung tissue